CN106691904A - 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 - Google Patents
一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 Download PDFInfo
- Publication number
- CN106691904A CN106691904A CN201510527307.1A CN201510527307A CN106691904A CN 106691904 A CN106691904 A CN 106691904A CN 201510527307 A CN201510527307 A CN 201510527307A CN 106691904 A CN106691904 A CN 106691904A
- Authority
- CN
- China
- Prior art keywords
- preparation
- composition
- product
- skin care
- phases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 102000008186 Collagen Human genes 0.000 claims abstract description 16
- 108010035532 Collagen Proteins 0.000 claims abstract description 16
- 229920001436 collagen Polymers 0.000 claims abstract description 16
- 102000016267 Leptin Human genes 0.000 claims abstract description 14
- 108010092277 Leptin Proteins 0.000 claims abstract description 14
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 14
- 229940039781 leptin Drugs 0.000 claims abstract description 14
- 230000017531 blood circulation Effects 0.000 claims abstract description 11
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 9
- 230000028327 secretion Effects 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 45
- 238000003756 stirring Methods 0.000 claims description 45
- 239000006071 cream Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000010438 heat treatment Methods 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 19
- 238000004945 emulsification Methods 0.000 claims description 15
- 238000003809 water extraction Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 10
- 230000008439 repair process Effects 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 230000002929 anti-fatigue Effects 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 14
- 208000003251 Pruritus Diseases 0.000 abstract description 9
- 206010030113 Oedema Diseases 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 17
- 239000000284 extract Substances 0.000 description 15
- 238000003828 vacuum filtration Methods 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 12
- 238000013019 agitation Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229960001660 histamine phosphate Drugs 0.000 description 7
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 7
- 238000003331 infrared imaging Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000006101 laboratory sample Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000001045 blue dye Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000006160 differential media Substances 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Natural products NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000001931 thermography Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000863032 Trieres Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 tetrazolium salts Chemical class 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及生物技术领域,特别涉及一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法。本发明公开了一种组合物,该组合物能够提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白的合成。本发明经实验证实对皮肤安全无刺激,所得护肤组合物及制剂既能提高瘦素分泌水平,加速体脂代谢;又能够提高体内胶原蛋白的含量,改善降脂后皮肤的松弛、浮肿状态的功效,达到健康纤体,协同增效的目的。本发明经实验证实还兼具皮肤修复及活血、抗疲劳的功效。
Description
技术领域
本发明涉及生物技术领域,特别涉及一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法。
背景技术
随着人们生活水平的提高,肥胖成为影响人们生活质量的原因之一,尤其是对于女性而言。工作生活压力大、饮食不规律、女性生产原因、运动量少等等成为目前肥胖的主要成因。肥胖不仅影响美观,还容易影响健康。
目前消除肥胖的产品很多,分为内服药品及外用制剂。市售内服的减肥药品有两大类,胰脂肪酶抑制剂和作用于中枢神经系统的食欲抑制剂,食欲抑制剂由于可引起神经系统不良反应而被限制使用,胰脂肪酶抑制剂奥利司他通过抑制胰脂肪酶活性,进而抑制食物中脂肪的分解吸收而减肥。但因其会引起脂肪泻,可造成脂溶性维生素缺乏。最近还有报道其可引起肝功能损害。尽管中枢神经系统食欲抑制剂lorcaserin和Qsymia成为了FDA 13年来首次批准的减肥药,但其仍然存在大脑中枢和心血管系统等方面的安全不确定性。因此目前疗效好且无不良反应的减肥药基本没有。
外用减肥制剂,如瘦身霜、纤体霜等被炒得火热。但是市售瘦身霜等外用制剂的功效不容乐观,一些产品主要是靠辣椒素给皮肤带来“火辣”的感觉从而让消费者误认为脂肪在燃烧。还有的产品可以促进皮肤排汗,改善水肿从而起到瘦身的功效。由于其治标不治本的特性使其功效短暂易反弹。更甚者对皮肤会造成一定的伤害,带来皮肤松弛或老化等副作用。
因此,获得一种纤体瘦身效果好且持久,同时具有美肤功效的外用制剂具有重要的现实意义。
发明内容
有鉴于此,本发明提供一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法。该组合物或护肤品对皮肤安全无刺激,所得护肤组合物及制剂既能提高瘦素分泌水平,加速体脂代谢;又能够提高体内胶原蛋白的含量,改善降脂后皮肤的松弛、浮肿状态的功效,达到健康纤体,协同增效的目的。本发明经实验证实还兼具皮肤修复及活血、抗疲劳的功效。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种组合物,包括燕麦、苦橙花、莲叶和陈皮。
在本发明的一些具体实施方案中,所述组合物包括如下质量份的原料:
本发明还提供了所述组合物的制备方法,取配方量的所述原料粉碎后,水提、冷却、过滤,收集滤液,即得。
在本发明的一些具体实施方案中,所述制备方法中所述水提的温度为61℃~100℃,所述水提的时间为1~4h。
在本发明的一些具体实施方案中,所述制备方法中所述水提的温度为80℃~100℃,所述水提的时间为1~4h。
在本发明的一些具体实施方案中,所述制备方法中所述水提的原料与水的质量比为1:21~1:40。
在本发明的一些具体实施方案中,所述制备方法中所述水提的原料与水的质量比为1:30~1:40。
在本发明的一些具体实施方案中,所述制备方法中在水提之后还包括冷却、过滤、收集滤液的步骤。
在本发明的一些具体实施方案中,所述制备方法中所述过滤包括普通过滤和真空抽滤。
在本发明的一些具体实施方案中,所述普通过滤为100~200目过滤;
在本发明的一些具体实施方案中,所述真空抽滤为在布氏漏斗里铺滤纸,滤纸中间夹0.3~0.6cm硅藻土进行真空抽滤。
在本发明的一些具体实施方案中,所述真空抽滤为在布氏漏斗里铺两层滤纸,滤纸中间夹0.3~0.6cm硅藻土进行真空抽滤。
在本发明的一些具体实施方案中,过滤为提取液冷却后,100目过滤,滤出渣后进行真空抽滤。
在本发明的一些具体实施方案中,所述制备方法中所述冷却为冷却至20~30℃。
本发明还提供了所述制备方法制得的组合物。
本发明依据传统中医“整体、辨证、综合”思想,采用天然的植物功效原料,通过提高体内胶原蛋白的含量,改善降脂后皮肤的松弛、浮肿状态的功效,达到辅助纤体的功效。同时,通过ELISA法研究组合物对脂肪细胞分泌瘦素的影响,发现各组分协同使用可以使瘦素分泌提高。此外,本原料成分可疏通经络,使气血流畅,肌肉筋膜得气血营养。基于此得到一种以具有调节脂肪代谢水平、抗疲劳的纤体组合物。
本发明还提供了所述组合物和/或所述制备方法制得的组合物在制备纤体、护肤的药物、食品、保健品和/或护肤品中的应用。
本发明还提供了所述组合物和/或所述制备方法制得的组合物在制备提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白合成的药物、食品、保健品和/或护肤品中的应用。
本发明还提供了一种护肤品,包括所述组合物和/或所述制备方法制得的组合物以及护肤品中可接受的辅料。
在本发明的一些具体实施方案中,所述护肤品的剂型为膏剂、霜剂、精华、爽肤水、乳液或喷雾剂。
本发明还提供了所述护肤品的制备方法,其由如下质量份的原料制成:
所述制备方法包括如下步骤:
步骤1:将A相加热、搅拌,获得第一产品;
步骤2:将B相加热、搅拌,获得第二产品;
步骤3:将所述第一产品与第二产品混合,乳化,获得第三产品;
步骤4:将C相与所述第三产品混合,获得第四产品;
步骤5:取所述第四产品,搅拌、降温,加入D相、E相、F相,混合,冷却,即得。
在本发明的一些具体实施方案中,所述制备方法步骤1中所述加热的温度为80~85℃,所述加热的升温速率为1~2℃/min;所述加热的时间为30~35min;步骤1中所述搅拌的速率为20~60r/min。
在本发明的一些具体实施方案中,所述制备方法步骤2中所述加热的温度为80~85℃,所述加热的升温速率为1~2℃/min;所述加热的时间为30~35min;步骤1中所述搅拌的速率为20~60r/min。
在本发明的一些具体实施方案中,所述制备方法步骤3中所述混合的搅拌速率为30~50r/min;所述乳化为在2500~3500r/mim的条件下均质乳化3~5min。
在本发明的一些具体实施方案中,所述制备方法步骤4中所述混合的搅拌速率为30~50r/min。
在本发明的一些具体实施方案中,所述制备方法步骤5中所述搅拌的速率为30~50r/min;所述降温的温度为40~50℃,所述降温的速率为1~2℃/min。
在本发明的一些具体实施方案中,所述制备方法步骤5中所述冷却的温度为30℃~40℃。
在本发明的一些具体实施方案中,本发明提供的护肤品采用如下具体制备方法:
(1)A相投入油相锅,搅拌升温至80~85℃,搅拌速率20~60r/min,升温速率1~2℃/min,恒温30~35分钟溶解完全;
(2)将B相抽入水相锅,搅拌升温至80~85℃,(搅拌速率20~60r/min,升温速率1~2℃/min)恒温30~35分钟。
(3)乳化:在搅拌下(搅拌速率30~50r/min),先将油锅中的A相抽入乳化锅,再将B相全部抽入乳化锅,2500~3500r/mim均质乳化3~5min;
(4)在搅拌下将C相投入乳化锅,搅拌速率30~50r/min;
(5)在搅拌下,搅拌速率30~50r/min,降温至40~50℃,降温速率1~2℃/min,依次加入D、E、F相,搅拌均匀;
(6)搅拌冷却至40℃以下,出料,即得。
本发明还提供了所述制备方法制得的护肤品。
在本发明的一些具体实施方案中,所述制备方法制备得到的是纤体膏霜,利用本发明护肤组合物及护肤品领域常规方法及辅料也可以制备得到其他剂型,如精华、爽肤水、乳液、喷雾剂等。
实验证明,本发明提供的所述组合物和/或所述制备方法制得的组合物能够提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白的合成。
综上,本发明提供的所述组合物和/或所述制备方法制得的组合物具有纤体、护肤的功效。
本发明提供的护肤品推荐使用方法为:本发明组合物及膏霜均可以涂抹方法施于人体皮肤表面,如小腿、小臂等需要纤体部位,轻轻按摩直至吸收。
本发明经实验证实对皮肤安全无刺激,所得护肤组合物及制剂既能提高瘦素分泌水平,加速体脂代谢;同时又能够提高体内胶原蛋白的含量,改善降脂后皮肤的松弛、浮肿状态的功效,达到健康纤体,协同增效的目的。本发明经实验证实还兼具皮肤修复及活血的功效,在纤体的同时起到美肤效果。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示实施例1制备组合物小腿红外成像图;其中,图1(A)示试用前;图1(B)示试用后;
图2示实施例1制备组合物小臂红外成像图;其中,图2(A)示试用前;图2(B)示试用后;
图3示实施例4制备膏霜小腿红外成像图;其中,图3(A)示试用前;图3(B)示试用后;
图4示实施例4制备膏霜小臂红外成像图;其中,图4(A)示试用前;图4(B)示试用后。
具体实施方式
本发明公开了一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明提供的实施例所用原料均可通过市售购买获得,本发明使用原料的来源见表1,本发明所用的仪器名称及厂家见表2。
表1原料及其来源
表2仪器名及购买厂家
名称 | 型号 | 厂家 |
恒温水浴锅 | HH·S1-M | 北京长安科学仪器厂 |
智能控温加热搅拌器 | SZCL | 巩义市予华仪器有限公司 |
循环水式真空泵 | SHB-Ⅲ | 郑州长城科工贸有限公司 |
下面结合实施例,进一步阐述本发明:
实施例1本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取,混匀;
燕麦50g,苦橙花20g,莲叶20g,陈皮50g
(2)加水提取,原料与水的质量比为1:21,61℃提取3小时;
(3)将步骤(2)得到的提取液冷却至20℃,100目过滤,滤出渣后进行真空抽滤,收集滤液,即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸,滤纸中间夹0.3~0.6cm硅藻土进行真空抽滤。
实施例2本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取,混匀;
燕麦65g,苦橙花30g,莲叶10g,陈皮30g
(2)加水提取,原料与水的质量比为1:30,100℃提取1小时;
(3)将步骤(2)得到的提取液冷却至25℃,200目过滤,滤出渣后进行真空抽滤,收集滤液,即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸,滤纸中间夹0.3~0.6cm硅藻土进行真空抽滤。
实施例3本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取,混匀;
燕麦100g,苦橙花10g,莲叶30g,陈皮40g
(2)加水提取,原料与水的质量比为1:40,80℃提取4小时;
(3)将步骤(2)得到的提取液冷却至30℃,100目过滤,滤出渣后进行真空抽滤,收集滤液,即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸,滤纸中间夹0.3~0.6cm硅藻土进行真空抽滤。
实施例4本发明纤体膏霜的制备
组方及用量:
表3组方及用量
膏霜制备方法:
(1)A相投入油相锅,搅拌升温至80℃,搅拌速率40r/min,升温速率1℃/min,恒温30分钟溶解完全;
(2)将B相抽入水相锅,搅拌升温至80℃,(搅拌速率40r/min,升温速率1℃/min)恒温30分钟。
(3)乳化:在搅拌下(搅拌速率30r/min),先将油锅中的A相抽入乳化锅,再将B相全部抽入乳化锅,2500r/mim均质乳化3min;
(4)在搅拌下将C相投入乳化锅,搅拌速率30r/min;
(5)在搅拌下,搅拌速率30r/min,降温至40℃,降温速率1℃/min,依次加入D、E、F相,搅拌均匀;
(6)搅拌冷却至40℃,出料,即得。
实施例5本发明纤体膏霜的制备
组方及用量:
表4组方及用量
膏霜制备方法:
(1)A相投入油相锅,搅拌升温至82℃,搅拌速率20r/min,升温速率2℃/min,恒温35分钟溶解完全;
(2)将B相抽入水相锅,搅拌升温至82℃,(搅拌速率20r/min,升温速率2℃/min)恒温35分钟。
(3)乳化:在搅拌下(搅拌速率40r/min),先将油锅中的A相抽入乳化锅,再将B相全部抽入乳化锅,3000r/mim均质乳化4min;
(4)在搅拌下将C相投入乳化锅,搅拌速率40r/min;
(5)在搅拌下,搅拌速率40r/min,降温至45℃,降温速率2℃/min,依次加入D、E、F相,搅拌均匀;
(6)搅拌冷却至35℃,出料,即得。
实施例6本发明纤体膏霜的制备
组方及用量:
表5组方及用量
膏霜制备方法:
(1)A相投入油相锅,搅拌升温至85℃,搅拌速率60r/min,升温速率1℃/min,恒温32分钟溶解完全;
(2)将B相抽入水相锅,搅拌升温至85℃,(搅拌速率60r/min,升温速率2℃/min)恒温32分钟。
(3)乳化:在搅拌下(搅拌速率50r/min),先将油锅中的A相抽入乳化锅,再将B相全部抽入乳化锅,3500r/mim均质乳化5min;
(4)在搅拌下将C相投入乳化锅,搅拌速率50r/min;
(5)在抽真空搅拌下,搅拌速率50r/min,降温至50℃,降温速率2℃/min,依次加入D、E、F相,搅拌均匀;
(6)在抽真空搅拌冷却至30℃,出料,即得。
实施例7功效实验
一、实施例1、实施例2、实施例3制备所得纤体组合物对CCD-966SK细胞合成胶原蛋白的影响
1.1试验材料
人类皮肤纤维母细胞CCD-966SK台湾食品工业研究所;MEM细胞培养液(Minimum Essential Medium,Earle's)、胎牛血清、非必需氨基酸、丙酮酸钠Invitrogen公司;二甲基亚砜Sigma公司;WST-1(水溶性四唑盐)Abnova公司;胶原检测试剂盒Biocolor公司;实施例制备样品
1.2主要仪器
BP3100S电子天平:SARTORIUS公司;SZCL智能控温加热搅拌器:巩义市予华仪器有限公司;SHB-Ⅲ型循环水式真空泵;CO2培养箱(美国,M-1815TC),液体闪烁计数仪(国营二六二厂,FJ-2107型),台式冷冻高速离心机Sigma4K15为美国Sigma公司产品;真空冷冻干燥仪ADVANTAGE为美国Ⅵ潞公司产品;Multiskan GO酶标仪:Thermo。
1.3实验方法
将人类皮肤纤维母细胞CCD-966SK,以MEM培养基(其中含10%FBS、1%青-链霉素、1%非必需氨基酸以及1%丙酮酸钠)在5%CO2、37℃条件下培养,每2~3d换液。对细胞增殖的作用:按照每孔1×104个CCD-966SK细胞接种于96孔板,并加入样品(以含10%胎牛血清的MEM全培养液配制),每孔总体积100μL。胶原蛋白的含量采用胶原蛋白检测试剂盒(Sircol Collagen assay)测定。
1.4实验结果
测定实施例1、实施例2、实施例3得到纤体组合物对人类皮肤纤维母细胞CCD-966SK合成胶原蛋白的影响。实验空白组不含植物提取物。实验结果见表6。结果表明,实施例1、实施例2、实施例3得到植物提取物对CCD-966SK细胞胶原蛋白合成具有显著的促进作用(P<0.05)。
表6实验结果
样品名称 | 胶原蛋白浓度(mg/mL) |
空白组 | 0 |
实施例1 | 0.02 |
实施例2 | 0.03 |
实施例3 | 0.03 |
二、实施例1、实施例2、实施例3制备纤体组合物对脂肪细胞分泌瘦素的影响
1、增殖培养基的配制(1000ml)
D-MEM/F-12(1:1)干粉加去离子水850mL,待全部溶解后加入NaHCO32.44g、HEPES 3.15g,定容至1000ml,用0.1N的HCL和NaOH调节pH到7.2,0.22um滤膜过滤除菌分装,4℃保存备用。用时无菌添加10%灭活小牛血清作为增殖培养基或无菌添加10%灭活胎牛血清作为基础培养基。
2、分化培养基Ⅰ配制(100ml)
向基础培养基中添加胰岛素(10ug/mL)、地塞米松(1uM)、IBMX(0.5mM),经0.22um滤膜过滤除菌分装,储存于4℃。用时分别无菌添加10%灭活胎牛血清和双抗作为分化培养基Ⅰ。
3、分化培养基Ⅱ配制(100ml)
向基础培养基中添加胰岛素1mg,制成100mL分化培养基,得到胰岛素终浓度为10ug/ml的培养基。经0.22um滤膜过滤除菌分装,储存于4℃。用时无菌添加10%灭活胎牛血清作为分化培养基Ⅱ。
4、细胞培养
3T3-Ll前脂肪细胞株用含10%小牛血清的增殖培养基在37℃、5%CO2培养箱中培养,每2~3天换液一次,细胞长至50%~60%左右进行传代培养。前脂肪细胞的诱导分化按经典鸡尾酒法进行培养。调节细胞密度至2×105个/m1,定量接种于6孔培养板或24孔培养板中传代培养。2~3天更换培养基一次,直至细胞单层融合后,换为含10%胎牛血清的基础培养基培养2天,之后换为诱导液Ⅰ诱导细胞分化48小时,此后换诱导液Ⅱ继续培养,再48小时后,用含10%胎牛血清的基础培养基培养细胞,每48小时换液一次。7天后,90%以上的细胞形态近于圆形,胞浆内充满脂滴,即为分化成熟的脂肪细胞。
5、ELISA法测定不同浓度Act对脂肪因子的影响
每组设定3个平行孔。第10天收集细胞上清,按试剂盒说明测定瘦素含量。设定对照组,在分化第8天给药。
实施例1至3制备产品刺激成熟脂肪细胞分泌瘦素的结果见表7,由表7可以看出实施例1至3制备产品可以刺激成熟脂肪细胞分泌瘦素,瘦素释放水平逐渐增加。
表7实验结果
三、实施例1制备纤体提取物及实施例4制备纤体膏霜对豚鼠皮肤瘙痒模型的消炎作用实验
1试验材料1.1实验样品:实施例1制备纤体提取物、实施例4制备纤体膏霜
1.2实验动物:健康豚鼠,SPF/VAF级,雌雄各半,体重250±10g。由北京金牧阳实验动物养殖有限责任公司提供,动物合格证号:SCXK(京)2010-0001。饲养环境:北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂:磷酸组胺,Sigma公司产品。
2试验方法
2.1剂量设计:受试品以0.15ml/1cm2、0.1ml/1cm2、0.05ml/1cm2局部涂抹分别作为大剂量、中剂量组和小剂量组。模型对照组给予0.1ml/1cm2蒸馏水局部涂抹。
2.2磷酸组织胺致痒法:取豚鼠36只,于实验前1天右后足背剃毛,随机分组:模型对照组、大剂量组、中剂量组和小剂量组。连续3天于剃毛处分别均匀涂抹相应剂量受试品,模型对照组给予蒸馏水涂抹。实验第3天,精密称取磷酸组胺适量,临用前以蒸馏水配成0.01%、0.02%、0.03%、0.04%、0.05%、0.06%、0.07%、0.08%、0.09%、0.10%梯度浓度备用。用粗砂纸将豚鼠右后足背剃毛处擦伤,面积约1cm2,局部再涂药1次,于末次涂药10min后在擦伤处滴0.01%磷酸组胺0.05mL,以后每隔3分钟依0.01%、0.02%、0.03%、0.04%……递增浓度,每次均为0.05mL。直到出现豚鼠回头舔右后足,以最后出现豚鼠回头舔右后足时所滴取的磷酸组胺总量为致痒阈。计算各组致痒阈并比较组间的差异性。
3试验结果
结果显示,使用磷酸组胺致痒后,豚鼠出现回头舔右后足行为。使用受试品涂抹致痒部位后,大剂量组受试品可显著提高豚鼠磷酸组胺致痒阈,与模型对照组比较有显著性差异(P<0.05)。结果见表8。
表8样品对豚鼠磷酸组胺致痒反应的影响(x±s,n=6)
注:与模型对照组比较,*P<0.05。
4试验结论
实施例1制备纤体提取物、实施例4制备所得纤体膏霜可有效的提高磷酸组胺致痒阈,证实了其缓解皮肤炎症、止痒的功效。
发明人用实施例2、实施例3制备纤体组合物、实施例5、实施例6制备纤体膏霜重复上述实验,得到相同的效果,与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P>0.05)。
四、实施例1及实施例4制备所得制剂皮肤修复作用功效评价
1试验材料1.1实验样品:实施例1制备纤体提取物、实施例4制备纤体膏霜
1.2实验动物:健康豚鼠,SPF/VAF级,36只,雌雄各半,体重250±10g。由北京金牧阳实验动物养殖有限责任公司提供,动物合格证号:SCXK(京)2010-0001。饲养环境:北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂及仪器:丙酮、乙醚,均为北京化工厂产品。皮肤含水量检测仪,
2试验方法
2.1剂量设计:受试品以0.15g/1cm2、0.1g/1cm2、0.05g/1cm2局部涂抹作为大剂量组、中剂量组和小剂量组。空白对照组和模型对照组给予0.1ml/1cm2蒸馏水局部涂抹。
2.2取豚鼠36只,于实验前1天颈背部剃毛,面积约为2×2cm2,随机分组:空白对照组、模型对照组、受试大剂量组、中剂量组和小剂量组。除空白对照组豚鼠,其余各组取丙酮:乙醚=1:1混合液150μl滴于去毛处,10分钟后分别取相应样品涂抹于去毛部位,一天2次,连续5天,空白对照组和模型对照组豚鼠给予蒸馏水涂抹于去毛处。于第5天给予样品后20分钟测量豚鼠脱毛处皮肤含水量,比较组间差异,并计算水分散失保护率。
样品对皮肤脱水模型皮肤含水量的影响,可以为评价样品对过敏皮肤的修复功效提供实验依据。
水分散失保护率(%)=(用药组皮肤含水量-模型组皮肤含水量)/空白对照组皮肤含水量×100
3试验结果
结果显示,豚鼠皮肤脱水后,模型对照组豚鼠皮肤脱水率为50.75%。使用受试品涂抹后,实施例1制备纤体植物组合物、实施例4制备纤体膏霜大剂量组可显著提高豚鼠皮肤含水量,与模型对照组比较有显著性差异(P<0.05)。结果见表9。
表9对过敏后皮肤的修复作用(x±s,n=6)
4试验结论
实施例1制备纤体组合物、实施例4制备所得纤体膏霜对皮肤修复功效明显。
发明人用实施例2、实施例3制备纤体制剂、实施例5、实施例6制备纤体膏霜重复上述实验,得到相同的效果,与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P>0.05)。说明本发明制备所得制剂具有良好的修复作用。
五、实施例1及实施例4制备所得制剂去红肿功效评价
1试验材料1.1实验样品:实施例1制备纤体提取物、实施例4制备纤体膏霜;
1.2实验动物:SD大鼠,SPF/VAF级,36只,雌雄各半,体重180±10g。由北京金牧阳实验动物养殖有限责任公司提供,动物合格证号:SCXK(京)2010-0001。饲养环境:北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂及仪器:anti-DNP IgE、DNP-HAS、伊文思蓝均为Sigma公司产品;丙酮为北京化工厂产品。RT-6000酶标仪为雷杜公司产品。
2试验方法
2.1剂量设计:受试品以0.15g/1cm2、0.1g/1cm2、0.05g/1cm2局部涂抹作为大剂量、中剂量组和小剂量组。空白对照组和模型对照组给予0.1g/1cm2蒸馏水局部涂抹。
2.2皮肤过敏实验
取大鼠36只,雌性,室温环境下分笼饲养,自由取食及摄水,适应性饲养5天后按体重随机分组,分别为空白对照组、模型对照组、受试品大剂量组、中剂量组和小剂量组,每组6只。背部剃毛后,除空白对照组外,其余各组大鼠背部选取3个点,每点皮下注射anti-DNP IgE 0.5μg(0.5μl)。48小时后,各组大鼠尾静脉注射含有4%伊文思蓝的DNP-HAS 100μg(100μl)。在尾静脉注射DNP-HAS前1小时,在给药各组大鼠背部,以注射anti-DNPIgE的点为中心,每点涂抹2cm2面积的相应药物。静脉注射DNP-HAS后30分钟处死大鼠。剪下蓝染皮肤,使用1:1丙酮-生理盐水混合溶液浸泡24h,离心取上清,用分光光度计于620nm处检测OD值。使用伊文思蓝溶液制作标准曲线,计算每只大鼠背部皮肤染料含量及PCA反应抑制率。抑制率计算公式如下:
3试验结果
结果显示,致敏后大鼠局部皮肤蓝染,使用受试品涂抹后,受试品可显著降低大鼠蓝染皮肤染料含量,与模型对照组比较均有显著性差异或极显著差异(P<0.01,P<0.05),结果见表10。
表10样品对大鼠PCA反应的影响
4试验结论
实施例1制备纤体提取物、实施例4制备所得纤体膏霜显著降低致敏大鼠蓝染皮肤染料含量,说明本发明制剂具有潜在的消除外援刺激引起的红肿功效。
发明人用实施例2、实施例3、实施例5、实施例6制备制剂重复上述实验,得到相同的效果,与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P>0.05)。
六、实施例1制备组合物、实施例4制备膏霜抗疲劳功效评价
近年来,由于久坐不动、过度的脑力劳动引起的慢性疲劳成为办公室工作者常见问题,主要表现为肩胛、脖颈等的疼痛及不适,这严重影响了人们的工作效率及生活质量。用本实施例制备样品在抗疲劳功效方面进行评价,评价方法如下:
实验样品:实施例1所得植物组合物、实施例4所得膏霜;
实验对象:30名具有脖颈疼痛症状的办公室工作人员,随机分为两组,每组15人,分别试用实施例1制备组合物、实施例4制备膏霜;
使用方法:脖颈等酸痛处涂抹、按摩,每天2次,早晚各一次,持续4周。
评价标准:疗效显著:疼痛症状消失;症状缓解:疼痛症状减轻;无效:试用前后无明显变化;有效:疗效显著和症状缓解;
对30名试用者的使用结果统计如表11:
表11样品抗疲劳试用效果评价
显著 | 缓解 | 无效 | 有效率(%) | |
实施例1 | 2 | 6 | 7 | 53% |
实施例4 | 3 | 7 | 5 | 67% |
评价结果表明,本发明制备组合物及膏霜制剂均具有舒缓酸痛感、抗疲劳的功效,用实施例2、实施例3、实施例5、实施例6制备得样品重复上述,得到相同的结果,与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P>0.05)。
七、实施例1及实施例4制备所得制剂活血功效评价
实验方法
实验样品:实施例1所得植物提取物、实施例4所得膏霜。
涂抹方式:小腿、小臂涂抹,每天2次,早晚各一次,持续4周。
评价方法:护肤品的活血滋养功效可通过红外热成像图评价。皮肤的红外热成像图可以检测到受试部位血流速度及温度,可以反映气血运行情况,血流速度快、温度高,则气血好。通过对比试用前后的红外成像图可评价样品的活血效果。实施例1制备组合物对小腿、小臂红外成像如图1、图2所示,实施例4制备膏霜对小腿、小臂红外成像如图3、图4所示。皮肤红外热成像结果显示,试用者在使用样品后(如图1(B)、图2(B)、图3(B)、图4(B)所示),皮肤的血流速度提升(图中,受试部位颜色偏淡的部位,血流速度快)。
红外热成像实验证实,实施例1、实施例4所得样品具有良好的促进血液循环功效,对实施例2、实施例3、实施例5及实施例6制备所得样品进行同样的试验,结果同上,与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P>0.05)。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (12)
1.一种组合物,其特征在于,包括燕麦、苦橙花、莲叶和陈皮。
2.根据权利要求1所述的组合物,其特征在于,包括如下质量份的原料:
3.根据权利要求1或2所述的组合物的制备方法,其特征在于,取配方量的所述原料粉碎后,水提。
4.根据权利要求3所述的制备方法,其特征在于,所述水提的温度为61℃~100℃,所述水提的时间为1~4h;
所述水提的原料与水的质量比为1:21~1:40。
5.根据权利要求3或4所述的制备方法制得的组合物。
6.根据权利要求1或2或5所述的组合物在制备纤体、护肤的药物、食品、保健品和/或护肤品中的应用。
7.根据权利要求1或2或5所述的组合物在制备提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白合成的药物、食品、保健品和/或护肤品中的应用。
8.一种护肤品,其特征在于,包括如权利要求1或2或5所述的组合物和护肤品中可接受的辅料。
9.根据权利要求8所述的护肤品,其特征在于,所述护肤品的剂型为膏剂、霜剂、精华、爽肤水、乳液或喷雾剂。
10.根据权利要求8或9所述的护肤品的制备方法,其特征在于,其由如下质量份的原料制成:
所述制备方法包括如下步骤:
步骤1:将A相加热、搅拌,获得第一产品;
步骤2:将B相加热、搅拌,获得第二产品;
步骤3:将所述第一产品与第二产品混合,乳化,获得第三产品;
步骤4:将C相与所述第三产品混合,获得第四产品;
步骤5:取所述第四产品,搅拌、降温,加入D相、E相、F相,混合,冷却,即得。
11.根据权利要求10所述的制备方法,其特征在于,步骤1中所述加热的温度为80~85℃,所述加热的升温速率为1~2℃/min;所述加热的时间为30~35min;步骤1中所述搅拌的速率为20~60r/min;
步骤2中所述加热的温度为80~85℃,所述加热的升温速率为1~2℃/min;所述加热的时间为30~35min;步骤1中所述搅拌的速率为20~60r/min;
步骤3中所述混合的搅拌速率为30~50r/min;所述乳化为在2500~3500r/mim的条件下均质乳化3~5min;
步骤4中所述混合的搅拌速率为30~50r/min;
步骤5中所述搅拌的速率为30~50r/min;所述降温的温度为40~50℃,所述降温的速率为1~2℃/min;
步骤5中所述冷却的温度为30℃~40℃。
12.根据权利要求10或11所述的制备方法制得的护肤品。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510527307.1A CN106691904A (zh) | 2015-08-24 | 2015-08-24 | 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 |
EP16838244.8A EP3342417B1 (en) | 2015-08-24 | 2016-03-16 | Composition for body slimming and skin care and preparation method thereof |
US15/746,408 US20180200181A1 (en) | 2015-08-24 | 2016-03-16 | Composition for body slimming and skin care and preparation method thereof |
JP2018506987A JP2018522923A (ja) | 2015-08-24 | 2016-03-16 | 痩身ならびにスキンケア用組成物、および、その調製方法 |
PCT/CN2016/076485 WO2017031981A1 (zh) | 2015-08-24 | 2016-03-16 | 一种纤体护肤的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510527307.1A CN106691904A (zh) | 2015-08-24 | 2015-08-24 | 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106691904A true CN106691904A (zh) | 2017-05-24 |
Family
ID=58099363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510527307.1A Withdrawn CN106691904A (zh) | 2015-08-24 | 2015-08-24 | 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180200181A1 (zh) |
EP (1) | EP3342417B1 (zh) |
JP (1) | JP2018522923A (zh) |
CN (1) | CN106691904A (zh) |
WO (1) | WO2017031981A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110974751A (zh) * | 2019-12-31 | 2020-04-10 | 武汉洛园生物科技有限公司 | 一种纤体瘦身化妆品组合物及其制作方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7214356B2 (ja) * | 2018-03-22 | 2023-01-30 | 株式会社 資生堂 | レプチンを指標とする肌色悪化リスク評価方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593177A (zh) * | 2004-07-01 | 2005-03-16 | 汕头市生奥保健食品有限公司 | 一种蔬果花草茶及其制作方法 |
CN1596686A (zh) * | 2004-09-21 | 2005-03-23 | 邓运林 | 绿色生态保健茶及其生产方法 |
CN101766556A (zh) * | 2008-12-31 | 2010-07-07 | 云南恒冠实业有限公司 | 一种纤体瘦身化妆品组合物 |
CN101856390A (zh) * | 2010-06-01 | 2010-10-13 | 苏风顺 | 一种纤体中药膏剂 |
CN104224603A (zh) * | 2013-06-23 | 2014-12-24 | 青岛道合生物科技有限公司 | 一种植物抗氧化爽肤水 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3441215B2 (ja) * | 1995-03-01 | 2003-08-25 | 花王株式会社 | 入浴剤組成物 |
JPH09295932A (ja) * | 1996-05-02 | 1997-11-18 | Nonogawa Shoji Kk | 化粧料用痩身剤組成物 |
US6464991B1 (en) * | 1999-05-04 | 2002-10-15 | Finetex, Inc. | Oat lipid based surfactants and derivatives and process for preparing same |
FR2802811B1 (fr) * | 1999-12-24 | 2002-02-15 | Silab Sa | Procede d'extraction d'un principe actif a partir de petales de bigarade, notamment pour le traitement de la cellulite, principe actif obtenu, compositions cosmetiques et traitements adaptes |
JP2003286129A (ja) * | 2002-03-27 | 2003-10-07 | Hakugen:Kk | 痩身シート材 |
JP2004059545A (ja) * | 2002-07-31 | 2004-02-26 | Noevir Co Ltd | ヒスタミンh1受容体遮断剤 |
JP4034681B2 (ja) * | 2003-03-28 | 2008-01-16 | リンナイ株式会社 | ガラストップコンロ |
JP2004307365A (ja) * | 2003-04-03 | 2004-11-04 | Kao Corp | 脂肪分解促進剤 |
JP4691320B2 (ja) * | 2003-12-26 | 2011-06-01 | 株式会社資生堂 | 脂肪蓄積抑制用組成物 |
JP4634768B2 (ja) * | 2004-10-04 | 2011-02-16 | 独立行政法人産業技術総合研究所 | 皮膚老化防止効果向上剤、その製造方法、それを用いた皮膚老化防止用組成物及びそれを含有する皮膚外用剤。 |
FR2946529B1 (fr) * | 2009-06-10 | 2011-09-09 | Lvmh Rech | Utilisation d'un extrait de cereale, en tant qu'agent actif amincissant dans une composition cosmetique amincissante |
CN103621993A (zh) * | 2012-08-28 | 2014-03-12 | 浙江劲膳美生物科技有限公司 | 一种气虚食疗配餐或代餐品 |
CN104286657A (zh) * | 2014-09-28 | 2015-01-21 | 赵敬哲 | 一种水果养颜粥及其制备方法 |
CN104286658A (zh) * | 2014-09-29 | 2015-01-21 | 刘韶娜 | 一种减肥粥及其制备方法 |
CN104473045A (zh) * | 2014-11-11 | 2015-04-01 | 明光市白云面粉有限公司 | 一种适合三高人群的保健米粉及其制备方法 |
-
2015
- 2015-08-24 CN CN201510527307.1A patent/CN106691904A/zh not_active Withdrawn
-
2016
- 2016-03-16 US US15/746,408 patent/US20180200181A1/en not_active Abandoned
- 2016-03-16 WO PCT/CN2016/076485 patent/WO2017031981A1/zh active Application Filing
- 2016-03-16 JP JP2018506987A patent/JP2018522923A/ja active Pending
- 2016-03-16 EP EP16838244.8A patent/EP3342417B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593177A (zh) * | 2004-07-01 | 2005-03-16 | 汕头市生奥保健食品有限公司 | 一种蔬果花草茶及其制作方法 |
CN1596686A (zh) * | 2004-09-21 | 2005-03-23 | 邓运林 | 绿色生态保健茶及其生产方法 |
CN101766556A (zh) * | 2008-12-31 | 2010-07-07 | 云南恒冠实业有限公司 | 一种纤体瘦身化妆品组合物 |
CN101856390A (zh) * | 2010-06-01 | 2010-10-13 | 苏风顺 | 一种纤体中药膏剂 |
CN104224603A (zh) * | 2013-06-23 | 2014-12-24 | 青岛道合生物科技有限公司 | 一种植物抗氧化爽肤水 |
Non-Patent Citations (4)
Title |
---|
佐佐木熏监修: "《健康养生花草茶》", 31 January 2003 * |
刘莉主编: "《美容养颜药膳大全》", 30 April 2012 * |
宋丽雅,何聪芬编著: "《化妆品植物功效添加剂的研究与开发》", 30 September 2011 * |
张理平: "陈皮研究新进展", 《光明中医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110974751A (zh) * | 2019-12-31 | 2020-04-10 | 武汉洛园生物科技有限公司 | 一种纤体瘦身化妆品组合物及其制作方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3342417A4 (en) | 2019-02-27 |
US20180200181A1 (en) | 2018-07-19 |
WO2017031981A1 (zh) | 2017-03-02 |
JP2018522923A (ja) | 2018-08-16 |
EP3342417B1 (en) | 2021-08-18 |
EP3342417A1 (en) | 2018-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102204995B (zh) | 一种益肾补酒及其制备方法 | |
CN101791283B (zh) | 一种可消除妊娠纹和疤痕的化妆品 | |
CN105936927A (zh) | 一种核桃低聚肽及其制备工艺和用途 | |
CN101904946B (zh) | 一种全效茶薰天然活性脂肪抑制配方 | |
CN106387899A (zh) | 一种美白祛斑抗皱嫩肤的功能性产品 | |
CN107847401A (zh) | 防脱发及生发组合物 | |
KR20140147948A (ko) | 항비만효과를 갖는 장수풍뎅이 유충 추출물의 제조방법 및 이를 포함하는 항비만 조성물 | |
CN107049824A (zh) | 一种具有美白功效的组合物及其在化妆品中的应用 | |
CN110302223A (zh) | 一种用于修复毛囊的育发液制剂及其制备方法 | |
CN103976110A (zh) | 一种雪菊茶珍及其制备方法 | |
CN108236656A (zh) | 一种增强免疫力、养颜美容、滋润女性肾功能的膏滋 | |
CN110151848A (zh) | 橘皮发酵物及其制备方法与应用 | |
CN102188467B (zh) | 一种扶正固本、增强人体免疫力、抗疲劳、抗肿瘤、延缓衰老的中药组合物 | |
US8715650B2 (en) | Bathing composition and method for preparing same | |
CN106691904A (zh) | 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法 | |
CN104800094A (zh) | 一种防妊娠纹腹膜 | |
CN108635326A (zh) | 一种含有石斛干细胞提取物抗衰老祛皱组合物及其用途 | |
KR101491771B1 (ko) | 흰점박이꽃무지 현탁액의 제조방법 및 이를 포함하는 항비만 조성물 | |
CN1777418B (zh) | 减肥组合物 | |
CN107136281A (zh) | 一种用于改善女性肾功能的昆布虫草压片糖果及其制备方法 | |
CN101744165A (zh) | 一种女子养颜保健食品 | |
CN106166123A (zh) | 具有抗敏止痒功效的护肤组合物、乳液及其制备方法 | |
CN101810556B (zh) | 具有抗皮肤衰老作用的中药提取物的组合物及制法和用途 | |
CN108721202A (zh) | 一种玫瑰茄干细胞冻干粉眼霜及其制备方法 | |
CN102228494A (zh) | 一种扶正固本、增强人体免疫力、抗疲劳、抗肿瘤、延缓衰老的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170524 |
|
WW01 | Invention patent application withdrawn after publication |